Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

Clinical trials for patients whose PSA rises while they are on androgen deprivation therapy but prostate cancer has not metastasized. (Stage 4)

CV CARE: CardioVascular Care in PC Patients

NCT Number: NCT06202820
Phase: NA
Trial Summary: This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with th – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym
:

A Trial for a Preliminary Estimate of the Effectiveness of a Novel Theoretical Framework

NCT Number: NCT06461416
Phase: NA
Trial Summary: Aim 1: To determine the preliminary effect sizes of al ActiveHeal EST (Engage-Sustain-Triumph) Program on occupational resilience. – clinicaltrials.gov for more information and locations
* Aim 2: To determine the preliminary effect sizes of ActiveHeal ES – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Arkansas
Acronym
:

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk

NCT Number: NCT06237179
Phase: PHASE1|PHASE2
Trial Summary: To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak & 6-minute walk distance [6MWD]) among prostate cancer (PC) patients – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Virginia Commonwealth University
Acronym
: EXTRA-PC

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT Number: NCT06242470
Phase: PHASE1
Trial Summary: The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): MacroGenics
Acronym
:

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

NCT Number: NCT06257758
Phase: PHASE1|PHASE2
Trial Summary: The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers. There are two part – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Valerio Therapeutics
Acronym
:

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

NCT Number: NCT05000294
Phase: Phase 1| Phase 2
Trial Summary: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective tr – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): University of Florida
Acronym
:

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

NCT Number: NCT05530655
Phase: Early Phase I
Trial Summary: This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): University of Rochester
Acronym
:

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

NCT Number: NCT04337580
Phase: Phase 2
Trial Summary: The purpose of this research study is to find out what effects (good and bad) omeprazole and cabazitaxel, or omeprazole and docetaxel, has on participants and their condition. Inve – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Wake Forest University Health Sciences
Acronym
: FASN

Video Education With Result Dependent dIsclosure

NCT Number: NCT05225428
Phase: Not Applicable
Trial Summary: The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym
: VERDI

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

NCT Number: NCT05471414
Phase: Not Applicable
Trial Summary: The study is comparing the effect on weight of providing home-delivered whole-food, plant-based meals versus standard, general nutritional counseling to men with prostate cancer on androgen-deprivatio – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym
: WFPBD

African Cancer Genome: GMD

NCT Number: NCT05754658
Phase:
Trial Summary: he goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fox Chase Cancer Center
Acronym
:

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy

NCT Number: NCT05869682
Phase: PHASE2
Trial Summary: This phase II trial tests how well bright white light (BWL) therapy works in reducing cancer-related fatigue and depression in patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant pa – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center
Acronym
:

The Genomic Medicine at VA Study

NCT Number: NCT04331535
Phase: Not Applicable
Trial Summary: This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Boston VA Research Institute, Inc.
Acronym
: GenoVA

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT Number: NCT04585750
Phase: Phase 1|Phase 2
Trial Summary: This study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 alone and in combination with pembrolizumab in participants with advanced solid tumors containing a TP5 – clinicaltrials.gov for more information and locations and locations
Clinicaltrials.gov
Trial Sponsor(s): PMV Pharmaceuticals, Inc
Acronym
:

Collection of Blood From Patients With Cancer

NCT Number: NCT00034216
Phase:
Trial Summary: This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and ol – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym
:

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

NCT Number: NCT04995198
Patient Summary
Phase:
Trial Summary: PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants by prospectively screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic evidence of disease and receiving systemic therapy for prostate cancer. Patients at all stages of disease will be welcome to participate in the PROMISE Registry. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Prostate Cancer Clinical Trials Consortium
Acronym
:

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

NCT Number: NCT05864144
Phase: PHASE1|PHASE2
Trial Summary: Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cem – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sensei Biotherapeutics, Inc.
Acronym
:

Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers

NCT Number: NCT05519878
Phase: Not Applicable
Trial Summary: This clinical trial evaluates light therapy and occupational therapy in improving cancer related fatigue (CRF) patients with genitourinary cancers. Light therapy is a non-pharmacological and evidence- – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI)
Acronym
:

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

NCT Number: NCT05605522
Phase: Phase 1
Trial Summary: This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fusion Pharmaceuticals Inc.
Acronym
:

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

NCT Number: NCT05629494
Phase: Phase 4
Trial Summary: Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and ele – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Albany Medical College
Acronym
: ADAPT-PSA

Improving Germline Testing in At-Risk Patients With Prostate Cancer

NCT Number: NCT05470036
Phase: Not Applicable
Trial Summary: A quality improvement initiative to improve rates of germline testing among men with prostate cancer through the use of an in-clinic educational sessi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, San Diego
Acronym
: IMPRINT

Social Risk Factors and Discrimination in Cancer Survivorship

NCT Number: NCT05301114
Phase: NA
Trial Summary: The objective of the proposed study is to scale social risk factor screening and referral for cancer survivors and to solidify information exchange between clinical and community s – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Medstar Health Research Institute
Acronym
:

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

NCT Number: NCT05036226
Phase: Phase 1|Phase 2
Trial Summary: The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydro – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Medical University of South Carolina
Acronym
: COAST

Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer

NCT Number: NCT04981834
Phase: Not Applicable
Trial Summary: This phase III trial compares the effects of robot-assisted radical prostatectomy (RARP) with or without vesicopexy on urinary continence (a person’s ability to control their bladd – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Southern California|National Cancer Institute (NCI)
Acronym
:

Improving Care After Inherited Cancer Testing

NCT Number: NCT04763915
Phase: NA
Trial Summary: The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genet – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Vanderbilt-Ingram Cancer Center
Acronym
: IMPACT

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

NCT Number: NCT04478279
Phase: Phase 1|Phase 2
Trial Summary: This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in pati – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sapience Therapeutics
Acronym
:

Onco-primary Care Networking to Support TEAM-based Care

NCT Number: NCT04258813
Phase: NA
Trial Summary: The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Duke University
Acronym
: ONE TEAM

Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors

NCT Number: NCT03880422
Phase: Not Applicable
Trial Summary: This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nu – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Roswell Park Cancer Institute
Acronym
:

CyberKnife Dose Escalation Prostate Cancer Trial

NCT Number: NCT03822494
Phase: Not Applicable
Trial Summary: Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates wit – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Crozer-Keystone Health System
Acronym
: CK-DESPOT

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

NCT Number: NCT02769962
Phase: Phase 1|Phase 2
Trial Summary: Background: EP0057 consists of a sugar molecule cyclodextrin linked to a chemotherapy drug called camptothecin. The combined molecule or “nanoparticle drug conjugate” travels throu – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Acronym
:

Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer

NCT Number: NCT02016248
Phase: Not Applicable
Trial Summary: The purpose of this study is to determine the side effects and how effective CyberKnife stereotactic ablative body radiation (SABR) is in patients with prostate cancer. The CyberKn – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): MemorialCare Health System
Acronym
:

Find Your Trial

Low Risk

Intermediate Risk

High Risk

Cancer Recurrence

Non-Metastatic Castration Resistant

Metastatic Castration Sensitive

Metastatic Castration Resistant

Promise Registry - All Risk Levels

PROMISE is a nationwide registry of prostate cancer patients with inherited mutations by screening approximately 5,000 participants with a prostate cancer diagnosis. The PROMISE team is studying how these mutations affect patient outcomes.

This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.

Pin It on Pinterest